Pharma companies do not lose value because they lack ERP, MES, QMS, LIMS, regulatory, supply-chain, CMO, finance or BI systems. They lose value because each system sees only part of the molecule, batch, filing, quality, supply and commercial clock. Quantos sits above this stack and closes the decision loop — turning API sourcing exposure, batch expiry, CMO capacity, regulatory filing drift, cold-chain compliance, tender margin compression and working-capital pressure into forward risk, named ownership, measured outcome and learning.
Quantos is not a pharma analytics platform. It is a decision intelligence platform for pharma and life sciences companies — a closed-loop system that converts batch data, API sourcing signals, regulatory timelines, CMO capacity and commercial exposure into forward decisions that are owned, executed, measured and improved.
What changes: Quantos does not report expiry, launch delay or margin erosion after it exists. It detects where batch and molecule risk is forming, assigns the owner, watches the action, scores the outcome and carries the learning into the next supply, quality, regulatory and commercial cycle.The structural problem in pharma is not data availability. It is fragmented accountability. Supply, quality, regulatory, production, commercial, tender, inventory and cash signals are reviewed in different systems and different meetings. By the time leadership connects the pattern, the batch clock, filing window or margin window has already narrowed.
ERP records purchase orders, inventory, batch value, sales, receivables and payables. It does not ask whether today’s molecule movement becomes expiry exposure, delayed revenue or trapped cash next month.
Production systems track batch progress, capacity and release status. They rarely translate delay into launch slip, tender exposure, working-capital lock-up or revenue-at-risk.
Deviation, QC release, stability, testing and batch-release clocks are visible. The stack usually does not convert them into supply risk, customer SLA risk or commercial exposure.
RA tools store submissions, queries and open items. They do not always connect filing age to launch calendar, tender opportunity, revenue timing and molecule-level risk.
CMO slots, API lead times, alternate sourcing and buffer stock are often discussed manually. Quantos reads the clocks together before a single-source dependency becomes a launch failure.
BI can show expiry, stock, sales, margin and tender performance. It does not assign an owner, verify action, score outcome or improve the next molecule cycle.
Quantos turns pharma operating data into deterministic risk signals across API sourcing, batch expiry, QC release, CMO capacity, regulatory filing, tender pricing, demand forecast, cold-chain compliance, working capital and margin. Same input, same output, same rupee exposure — auditable across future cycles.
Quantos correlates API dependency, lead time, buffer stock, alternate source readiness and demand commitment to surface molecule-level supply exposure before the buffer window closes.
The system projects expiring stock across 30, 60 and 90-day horizons against velocity, institutional demand and liquidation options to distinguish recoverable stock from likely write-off.
CMO slot confirmation, demand forecast, API availability and launch calendar are read together so capacity shortage is surfaced before the PO or production window closes.
Open items, filing age, query response time and launch dependency are monitored as clocks. Quantos surfaces the filing that can push market entry by a quarter before leadership sees missed launch revenue.
Awarded tender prices are compared with API cost, packaging cost, freight, FX movement and service obligations to surface projected margin compression before the next bid repeats the same erosion.
QC release lead time, customer shipment commitment, inventory position and batch availability are reconciled so SLA risk is surfaced before credit notes, penalties or lost trust appear.
Temperature excursions, route failures, storage-zone anomalies and shipment-leg risk are correlated into one quality-risk signal instead of being left as isolated incidents.
Quantos tracks revenue concentration by molecule, institution, tender and geography, then combines it with forecast uncertainty and fulfilment risk to show where one buyer can distort the plan.
Quantos monitors whether its own predictions are weakening. When accuracy decays because market behaviour, tender pattern or molecule demand changed, it raises a risk against the forecast itself.
Filing status, API availability, CMO slot, batch readiness, packaging, pricing, distribution readiness and commercial plan are tracked as one launch-risk clock.
Inventory ageing, batch value, receivables, tender payments, vendor commitments and CMO advances are evaluated together to show where capital will lock before finance sees it.
Discounts, tender price decisions, alternate sourcing, freight routing, batch liquidation and institutional allocation are scored against outcome so the system learns which actions protected margin.
Quantos consumes signals from ERP, MES, QMS, LIMS, regulatory trackers, CMO files, supply-chain systems, sales data, tender records, finance systems and manual operating inputs. It does not replace those systems. It closes the loop they leave open: forecast → risk → action → outcome → score → learning.
Quantos reads molecule, batch, API, CMO, QC, RA, inventory, tender, sales and finance signals. The goal is not more data. The goal is usable truth that can be acted on.
A filing delay, batch-release delay, API lead-time gap or expiry curve becomes a named risk with rupee exposure, deadline, severity and source trail.
Every risk is routed to one accountable owner: Supply Chain, QA, Regulatory Affairs, Commercial Ops, CFO, CMO Management, Planning or Business Head.
Quantos checks whether the action reduced expiry exposure, protected margin, secured supply, preserved launch window, released working capital or simply moved the risk elsewhere.
The system records whether the decision worked against the original risk. That score becomes institutional memory, not a discussion lost inside a launch or supply review.
The next forecast, risk score, owner recommendation and action priority are influenced by what actually happened. Every batch and molecule cycle improves the next one.
Most pharma companies invest in analytics platforms, BI dashboards and forecasting tools. These systems describe what happened or estimate what may happen. They do not own decisions. Quantos operates as a decision intelligence platform for pharma — a system that converts signals into action, enforces ownership, measures outcomes and improves the next operational cycle.
Dashboards and reports summarise batch movement, inventory, demand and quality metrics.
Forecasting models estimate demand, expiry curves and supply behaviour based on historical patterns.
Quantos assigns ownership, verifies execution, scores outcomes and learns across batch, molecule and commercial cycles — making it a true decision intelligence system for pharma.
Pharma execution is multi-owner. Quantos translates the same forward risk into the decision language of Supply Chain, Regulatory Affairs, QA/QC, Commercial, CFO and CMO Management — without forcing them into another reporting ritual.
Quantos connects API lead time, alternate source readiness, CMO slot, batch status, demand forecast and buffer stock. It shows supply risk before the launch or tender commitment fails.
Quantos watches filing milestones, query response age, open documentation, launch dependency and historical closure patterns. RA sees which filing needs escalation before revenue timing slips.
Quantos links QC release, stability, deviations, batch availability, shipment commitment and cold-chain risk into one release-exposure view. QA/QC sees consequence, not isolated tickets.
Quantos connects tender price, API cost, packaging, freight, institutional concentration, expiry exposure and working capital. Finance sees molecule-level exposure before margin erosion becomes a quarterly explanation.
Signal → owner → action → outcome → learning. The objective is not reporting risk. The objective is reducing exposure before it becomes expiry write-off, launch delay, compliance exposure, tender loss or margin compression.
Quantos connected single-source API dependency, buffer coverage, CMO readiness and demand commitment. The operator saw a supply-risk window before the stockout turned into delayed revenue or customer loss.
Quantos projected batch expiry against velocity, institutional demand and discount options. The risk became recoverable stock, deliberate quarantine and write-off control — not an accidental quarter-end loss.
The filing delay looked like one regulatory open item. Quantos connected filing age, commercial launch calendar and expected demand, then surfaced delayed-revenue exposure before the market-entry window slipped.
Quantos correlated realised price drift, API landed cost, packaging, tender commitment and institutional concentration. The margin issue became an owned intervention before it became a quarterly explanation.
Quantos will show where your current pharma software stack stops — and how a closed-loop intelligence layer surfaces the risk, assigns the owner, measures the action and learns from the outcome.
